STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com.

Inquiries

Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005

Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.

Abcellera Biologics Inc.

NASDAQ:ABCL

ABCL Rankings

ABCL Latest News

ABCL Latest SEC Filings

ABCL Stock Data

1.09B
230.73M
22.94%
38.47%
14.47%
Biotechnology
Pharmaceutical Preparations
Link
Canada
VANCOUVER